225 related articles for article (PubMed ID: 12955684)
1. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
Richardson D; Lindley EJ; Bartlett C; Will EJ
Am J Kidney Dis; 2003 Sep; 42(3):551-60. PubMed ID: 12955684
[TBL] [Abstract][Full Text] [Related]
2. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
[TBL] [Abstract][Full Text] [Related]
3. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the iron metabolism and effectiveness of anemia treatment in patients on maintenance hemodialysis performed based on polysulfone and helixone dialyzers].
Sobaszek-Pitas M; Krzanowska K; Sułowicz W
Przegl Lek; 2014; 71(8):418-22. PubMed ID: 25546912
[TBL] [Abstract][Full Text] [Related]
5. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
6. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
7. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
8. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
Axelsson J; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P; Bárány P
Am J Kidney Dis; 2005 Oct; 46(4):628-34. PubMed ID: 16183417
[TBL] [Abstract][Full Text] [Related]
9. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
11. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers.
McCarthy JT; Jenson BM; Squillace DP; Williams AW
Am J Kidney Dis; 1997 Apr; 29(4):576-83. PubMed ID: 9100048
[TBL] [Abstract][Full Text] [Related]
12. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
14. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
15. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
16. Plasma carnitine profile during chronic renal anemia treatment with recombinant human erythropoietin.
Debska-Slizień A; Owczarzak A; Kunicka D; Lysiak-Szydłowska W; Rutkowski B
Int J Artif Organs; 2003 Jan; 26(1):33-8. PubMed ID: 12602467
[TBL] [Abstract][Full Text] [Related]
17. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
18. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
[TBL] [Abstract][Full Text] [Related]
19. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
[TBL] [Abstract][Full Text] [Related]
20. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
